[Pubmed] Successful Management of Generalized Myasthenia Gravis Induced by Atezolizumab in a Patient With Extensive-Stag
Posté : 17 oct. 2022 12:00
JTO Clin Res Rep. 2022 Jun 2;3(11):100354. doi: 10.1016/j.jtocrr.2022.100354. eCollection 2022 Nov.
ABSTRACT
Immune checkpoint inhibitors including atezolizumab and durvalumab have been approved as the first-line treatment in extensive-stage SCLC. However, immune checkpoint inhibitors can cause immune-related adverse events, which will lead to the shelving of follow-up treatment and the progression and deterioration of SCLC. Myasthenia gravis (MG) is a relatively rare and fatal presentation of immune-related adverse events, and experience with immune-related MG in patients with SCLC is limited. Herein we present a patient who developed generalized MG after receiving three cycles of treatment with etoposide, carboplatin, and atezolizumab. Immune-related MG was identified, with pyridostigmine bromide, intravenous immunoglobulin, and glucocorticoids given in time. Fortunately, the patient's MG was relieved, and treatment of SCLC was restarted subsequently.
PMID:36246044 | PMC:PMC9563168 | DOI:10.1016/j.jtocrr.2022.100354
Source: https://pubmed.ncbi.nlm.nih.gov/3624604 ... 7&v=2.17.8